Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on May 28, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). Voluntary payoff of approximately $55.1 million, including principal, interest, fees, costs and expenses.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Voluntary payoff of approximately $55.1 million, including principal, interest, fees, costs and expenses
- Loan Agreement fully terminated, eliminating all related covenants, debts and liabilities
- Repayment extinguished a $50 million borrowing at floating interest rates between 8.95% and 9.45%
- Removed interest-only payments through October 1, 2029, or October 1, 2030 upon regulatory milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.